Back to search results

Study of LY4170156 for Advanced Solid Tumors

This study is testing a new medicine called LY4170156 in people with advanced solid tumors, including ovarian, endometrial, cervical, non-small cell lung, and triple-negative breast cancers. Researchers want to find out if LY4170156 is safe, how well people tolerate it, and if it can help treat these cancers. LY4170156 may be given alone or with other approved cancer medicines like bevacizumab, carboplatin, or pembrolizumab. The study will also look for the best dose of LY4170156. You might be able to join if you are 18 or older and have one of the listed advanced solid tumors. The study plans to enroll about 495 people and will last up to approximately 4 years.

Study design
This is an interventional study with an unclear status, meaning it's not currently recruiting, active, or completed. It aims to enroll 495 participants and has two parts: dose-escalation/optimization (Phase 1a) and dose-expansion (Phase 1b).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints for determining the recommended dose are measured at 1 Cycle (21 days).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06400472

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Eli Lilly and Company
~495 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:LY4170156bevacizumabcarboplatinItraconazolepembrolizumab

At a glance

Recruiting sites
23 of 23 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156
Measured over 1 Cycle (21 days)
+5 more outcomes measured

Conditions

Ovarian Neoplasms
Endometrial Neoplasms
Uterine Cervical Neoplasms
Carcinoma, Non-Small-Cell Lung
Triple Negative Breast Neoplasms
Pancreatic Neoplasm
Colorectal Neoplasms

Explore related trials

Cervical CarcinomaColorectal CarcinomaEndometrial CarcinomaLung Non-Small Cell CarcinomaMalignant Ovarian NeoplasmPancreatic CarcinomaSolid NeoplasmTriple-negative breast cancer

Where it's being run

23 sites across 13 states
New York3
France3
Japan3
Spain3
Australia2
Italy2
Arizona1
California1

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have one of the following solid tumor cancers:
Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC)
Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer
Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, and TNBC

Exclusion

Individual with known or suspected uncontrolled central nervous system (CNS) metastases
Individual with history of carcinomatous meningitis
Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
Individual with evidence of corneal keratopathy or history of corneal transplant
Any serious unresolved toxicities from prior therapy
Significant cardiovascular disease
Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
History of pneumonitis/interstitial lung disease
Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention

What this trial measures

  • Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY41701561 Cycle (21 days)

    Number of participants with dose-limiting toxicities (DLTs)

  • Phase 1a: To determine the RP2D or optimal dose of LY4170156 with bevacizumab1 Cycle (21 days)

    Number of participants with DLTs

  • Phase 1a: To determine the RP2D or optimal dose of LY4170156 with carboplatin1 Cycle (21 days)

    Number of participants with DLTs

  • Phase 1a: To determine the RP2D or optimal dose of LY4170156 with pembrolizumab1 Cycle (21 days)

    Number of participants with DLTs

  • Phase 1b: To assess the antitumor activity of LY4170156 Monotherapy: Overall response rate (ORR)Up to Approximately 48 Months or 4 Years

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationUp to Approximately 48 Months or 4 Years

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module